keyword
MENU ▼
Read by QxMD icon Read
search

second-line

keyword
https://www.readbyqxmd.com/read/29684092/weekends-off-efavirenz-based-antiretroviral-therapy-in-hiv-infected-children-adolescents-and-young-adults-breather-extended-follow-up-results-of-a-randomised-open-label-non-inferiority-trial
#1
Anna Turkova, Cecilia L Moore, Karina Butler, Alexandra Compagnucci, Yacine Saïdi, Victor Musiime, Annet Nanduudu, Elizabeth Kaudha, Tim R Cressey, Suwalai Chalermpantmetagul, Karen Scott, Lynda Harper, Samuel Montero, Yoann Riault, Torsak Bunupuradah, Alla Volokha, Patricia M Flynn, Rosa Bologna, Jose T Ramos Amador, Steven B Welch, Eleni Nastouli, Nigel Klein, Carlo Giaquinto, Deborah Ford, Abdel Babiker, Diana M Gibb
BACKGROUND: Weekends off antiretroviral therapy (ART) may help engage HIV-1-infected young people facing lifelong treatment. BREATHER showed short cycle therapy (SCT; 5 days on, 2 days off ART) was non-inferior to continuous therapy (CT) over 48 weeks. Planned follow-up was extended to 144 weeks, maintaining original randomisation. METHODS: BREATHER was an open-label, non-inferiority trial. Participants aged 8-24yrs with virological suppression on efavirenz-based first-line ART were randomised 1:1, stratified by age and African/non-African sites, to remain on CT or change to SCT...
2018: PloS One
https://www.readbyqxmd.com/read/29684049/clinical-factors-associated-with-early-progression-and-grade-3-4-toxicity-in-patients-with-advanced-non-small-cell-lung-cancers-treated-with-nivolumab
#2
Coraline Dumenil, Marie-Ange Massiani, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Thierry Chinet, Etienne Giroux Leprieur
INTRODUCTION: The prognosis of advanced non-small-cell lung cancer (NSCLC) has been improved by development of immune checkpoint inhibitors (ICIs) such as nivolumab for second-line treatment. As phase III trials include only selected patients, we here investigated the clinical factors associated with efficacy and safety of nivolumab in 'real life' patients with advanced NSCLC. METHODS: Clinical and histological characteristics, therapies and survival data of all consecutive patients with advanced NSCLC included prospectively and treated by nivolumab in two French academic hospitals between February 2015 and December 2016 were examined...
2018: PloS One
https://www.readbyqxmd.com/read/29682855/clinical-outcomes-of-sorafenib-treatment-failure-for-advanced-hepatocellular-carcinoma-and-candidates-for-regorafenib-treatment-in-real-world-practice
#3
Uchikawa Shinsuke, Tomokazu Kawaoka, Hiroshi Aikata, Kenichiro Kodama, Yuno Nishida, Yuki Inagaki, Masahiro Hatooka, Kei Morio, Takashi Nakahara, Eisuke Murakami, Akira Hiramatsu, Masataka Tsuge, Michio Imamura, Yoshiiku Kawakami, Kazuaki Chayama
AIM: As second-line therapy, regorafenib has been shown to provide a survival benefit for patients with hepatocellular carcinoma (HCC) who progress on sorafenib. In this retrospective study, we assessed the clinical outcomes of sorafenib treatment failure with regard to second-line chemotherapy. METHODS: Patients (N=160) with advanced HCC, Child-Pugh A liver function and Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 treated with sorafenib between June 2009 and September 2016 were enrolled...
April 22, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29682621/surgery-for-metastatic-gastrointestinal-stromal-tumor-to-whom-and-how-to
#4
REVIEW
Hirotoshi Kikuchi, Yoshihiro Hiramatsu, Kinji Kamiya, Yoshifumi Morita, Takanori Sakaguchi, Hiroyuki Konno, Hiroya Takeuchi
Although imatinib is a standard treatment for metastatic or recurrent gastrointestinal stromal tumors (GISTs), acquired c-kit mutations reportedly cause secondary resistance to imatinib. Sunitinib is a tyrosine kinase inhibitor (TKI) that can be used as second-line therapy in imatinib-resistant or -intolerant GISTs. For sunitinib-resistant or -intolerant GISTs, regorafenib is a standard third-line treatment. Although TKI therapies have revolutionized the treatment of recurrent or metastatic GISTs, they cannot cure GISTs...
2018: Translational Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29682600/bevacizumab-with-metronomic-chemotherapy-of-low-dose-oral-cyclophosphamide-in-recurrent-cervical-cancer-four-cases
#5
Rose Isono-Nakata, Hiroshi Tsubamoto, Tomoko Ueda, Kayo Inoue, Hiroaki Shibahara
Standard chemotherapy for women with advanced or recurrent cervical cancer involves a combination of paclitaxel, platinum, and bevacizumab. However, for patients who experience anaphylaxis in response to paclitaxel or platinum, have permanent peripheral neuropathy, or develop early recurrence or progressive disease during first-line chemotherapy, the development of a non-taxane non-platinum regimen is mandatory. Clinical trials using anti-angiogenic treatment demonstrated favorable outcomes in cases of highly vascularized cervical cancer...
May 2018: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/29682242/eradication-of-helicobacter-pylori-in-iran-a-review
#6
REVIEW
Hafez Fakheri, Mehdi Saberi Firoozi, Zohreh Bari
Helicobacter pylori (H. pylori) infection is one of the most common bacterial infections, affecting almost half of the world's population. It is associated with peptic ulcer disease, gastric adenocarcinoma, and lymphoma. In Iran, the prevalence of H. pylori infection has been reported to be between 36% and 90% in different geographic regions. Several studies have assessed the efficacy of different therapeutic options for firstline and second-line H. pylori eradication in Iran; however, the results are conflicting...
January 2018: Middle East Journal of Digestive Diseases
https://www.readbyqxmd.com/read/29682179/antiapoptotic-bcl-2-proteins-determine-sorafenib-regorafenib-resistance-and-bh3-mimetic-efficacy-in-hepatocellular-carcinoma
#7
Anna Tutusaus, Milica Stefanovic, Loreto Boix, Blanca Cucarull, Aynara Zamora, Laura Blasco, Pablo García de Frutos, Maria Reig, Jose C Fernandez-Checa, Montserrat Marí, Anna Colell, Jordi Bruix, Albert Morales
Sorafenib, systemic treatment for advanced hepatocellular carcinoma (HCC), and regorafenib, novel second line treatment after sorafenib failure, have efficacy limited by evasive mechanisms of acquired-drug resistance. BCL-2 proteins participate in the response to tyrosine kinase inhibitors; however, their role in HCC therapy with sorafenib/regorafenib remains uncertain. BH3-mimetic ABT-263 (navitoclax) enhanced sorafenib activity, inducing cell death via a mitochondrial caspase-dependent mechanism, after BCL-xL/BCL-2 inhibition...
March 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29682027/decompressive-craniectomy-in-diffuse-traumatic-brain-injury-an-industrial-hospital-study
#8
Niraj Kumar Choudhary, Rinku Bhargava
Context: High intracranial pressure is the most frequent cause of mortality and disability after severe traumatic brain injury (TBI) which is treated by first-line therapeutic measures. When these measures fail, second-line therapies are started. Among second-line therapies, decompressive craniectomy (DC) has been used. It improves the functional outcome in these patients. Aim: This study aims to analyze the clinicoradiological factors associated with the prognosis of severe TBI in patients undergoing DC...
April 2018: Asian Journal of Neurosurgery
https://www.readbyqxmd.com/read/29681714/tamoxifen-is-better-than-low-dose-clomiphene-or-gonadotropins-in-women-with-thin-endometrium-7-mm-after-clomiphene-in-intrauterine-insemination-cycles-a-prospective-study
#9
Sunita Sharma, Geetha Rani, Gunja Bose, Indranil Saha, Sikha Bathwal, B N Chakravarty
Aim: Gonadotropin stimulation is used as the second line of treatment in patients with thin endometrium following clomiphene citrate (CC) administration, which is associated with higher cost, multiple births, and ovarian hyperstimulation syndrome. Tamoxifen (TMX), a selective estrogen receptor modulator, acts as an agonist on the endometrium. The objective of the present study was to compare the efficacy of low-dose CC, TMX, and gonadotropins in women with thin endometrium (<7 mm) following Clomiphene in intrauterine insemination (IUI) cycles...
January 2018: Journal of Human Reproductive Sciences
https://www.readbyqxmd.com/read/29681014/toxicity-and-quality-of-life-in-published-clinical-trials-for-advanced-lung-cancer
#10
Matjaz Zwitter
BACKGROUND: In every report on incurable disease, clear presentation of toxicity and of quality of life (QoL) is of essential importance. This postulate was assessed on a series of publications on systemic treatment for advanced lung cancer. MATERIALS AND METHODS: The analysis covered papers on original phase II-IV clinical trials published between 2013 and 2015 and included in the PubMed database. RESULTS: Selected for analysis were 349 publications on 333 trials with a total of 78...
April 21, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29680465/treatment-strategies-and-cumulative-live-birth-rates-in-who-ii-ovulation-disorders
#11
Sanne C Braam, Jan Peter de Bruin, Erato T I A Buisman, Monique Brandes, Willianne L D M Nelen, Jesper M J Smeenk, Jan Willem van der Steeg, Ben Willem J Mol, Carl J C M Hamilton
OBJECTIVE: To assess the live birth rate in women with WHO II anovulation and the proportion of women that need second or third line treatments if the initial therapy fails. STUDY DESIGN: In this multicenter cohort study we included couples with unfulfilled child wish who were referred to three fertility clinics in the Netherlands and selected women with a WHO II ovulation disorder as the only final infertility diagnosis (n = 468). RESULTS: The cumulative live birth rate of the total group was 82% (383/468)...
April 10, 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/29675611/ponatinib-as-second-line-treatment-in-chronic-phase-chronic-myeloid-leukemia-patients-in-real-life-practice
#12
Massimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, Massimiliano Bonifacio, Domenica Gangemi, Federica Sorà, Alessandra Iurlo, Luigiana Luciano, Antonella Gozzini, Massimo Gentile, Monica Bocchia, Debora Luzi, Alessandro Maggi, Nicola Sgherza, Alessandro Isidori, Monica Crugnola, Patrizia Pregno, Anna Rita Scortechini, Isabella Capodanno, Michele Pizzuti, Robin Foà
Scarce information is available on the use of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia (CP-CML) patients resistant and/or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. We collected data from 29 CML patients, with a median age of 54 years (range 32-72). Eleven patients had received dasatinib, 15 patients received nilotinib, and 3 patients received imatinib as first-line treatment. Forty-five percent of patients started ponatinib for secondary resistance, 38% for primary resistance, 7% for severe intolerance associated to a molecular warning, 7% due to the presence of a T315I mutation, and 3% for severe intolerance...
April 19, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29674766/the-combination-of-gemcitabine-cisplatin-and-paclitaxel-as-salvage-chemotherapy-for-advanced-urothelial-carcinoma
#13
Takeshi Hirata, Masanori Hanamoto, Kazuma Ogura, Nobuki Hayashi, Kosuke Takamura, Kohei Edamura, Shin Ebara, Takashi Saika
There is no standard second-line or salvage treatment for advanced urothelial carcinoma (UC). Here we investigated the efficacy and safety of gemcitabine, cisplatin, and paclitaxel (GCP) combination chemotherapy as salvage chemotherapy for advanced UC. We retrospectively analyzed the cases of 23 patients with advanced UC who showed progression or recurrence after cisplatin-based chemotherapy. Gemcitabine (1000 mg/m2), and paclitaxel (80 mg/m2) were administered on days 1 and 8. Cisplatin (70 mg/m2) was administered on day 1...
April 2018: Acta Medica Okayama
https://www.readbyqxmd.com/read/29674635/design-synthesis-biological-activity-and-structure-activity-relationship-studies-of-chalcone-derivatives-as-potential-anti-candida-agents
#14
Jéssica T Andrade, Felipe R S Santos, William G Lima, Carla D F Sousa, Lohanna S F M Oliveira, Rosy I M A Ribeiro, Ana J P S Gomes, Marcelo G F Araújo, José A F P Villar, Jaqueline M S Ferreira
Vulvovaginal candidiasis (VVC) affects millions of women around the world every year. Candida albicans is the most frequently isolated pathogen in women and its rapid ability to develop resistance to first and second line therapies has boosted the search for new and effective antifungal agents. In this study, we show the in vitro anti-Candida activity of fifteen synthetic chalcone analogs and their antifungal potential in an in vivo model of VVC. Chalcone 12 showed potent antifungal effects, being able to inhibit the growth of Candida spp...
April 19, 2018: Journal of Antibiotics
https://www.readbyqxmd.com/read/29674504/efficacy-of-bendamustine-and-rituximab-as-first-salvage-treatment-in-chronic-lymphocytic-leukemia-and-indirect-comparison-with-ibrutinib-a-gimema-eric-and-uk-cll-forum-study
#15
Antonio Cuneo, George Follows, Gian Matteo Rigolin, Alfonso Piciocchi, Alessandra Tedeschi, Livio Trentin, Angeles Medina Perez, Marta Coscia, Luca Laurenti, Gerardo Musuraca, Lucia Farina, Alfredo Rivas Delgado, Ester Maria Orlandi, Piero Galieni, Francesca Romana Mauro, Carlo Visco, Angela Amendola, Atto Billio, Roberto Marasca, Annalisa Chiarenza, Vittorio Meneghini, Fiorella Ilariucci, Monia Marchetti, Stefano Molica, Francesca Re, Gianluca Gaidano, Marcos Gonzalez, Francesco Forconi, Stefania Ciolli, Agostino Cortelezzi, Marco Montillo, Lukas Smolej, Anna Schuh, Toby A Eyre, Ben Kennedy, Kris M Bowles, Marco Vignetti, Javier de la Serna, Carol Moreno, Robin Foà, Paolo Ghia
We performed an observational study on the efficacy of bendamustine and rituximab as first salvage regimen in chronic lymphocytic leukemia. In an intention-to-treat analysis including 237 patients, the median progression free survival was 25 months. The presence of del(17p), unmutated IGHV and advanced stage were associated with a shorter progression free survival at multivariate analysis. The median time-to-next treatment was 31.3 months. Front-line treatment with a chemoimmunotherapy regimen was the only predictive factor for a shorter time to next treatment at multivariate analysis...
April 19, 2018: Haematologica
https://www.readbyqxmd.com/read/29673879/trimethoprim-susceptibility-in-e-coli-community-acquired-urinary-tract-infections-in-france
#16
C Duployez, J Robert, A Vachée
OBJECTIVES: Trimethoprim has been recently included in the French guidelines for the treatment of urinary tract infections, but no epidemiological data supports its use. We aimed to determine the trimethoprim susceptibility of Escherichia coli isolates responsible for community-acquired urinary tract infections in women of childbearing age. MATERIALS AND METHODS: We conducted a national prospective survey. A total of 350 strains of E. coli isolated from urines in 35 laboratories were included...
April 16, 2018: Médecine et Maladies Infectieuses
https://www.readbyqxmd.com/read/29673108/lenalidomide-versus-lenalidomide-dexamethasone-prolonged-treatment-after-second-line-lenalidomide-dexamethasone-induction-in-multiple-myeloma
#17
Johan Lund, Astrid Gruber, Birgitta Lauri, Adil Doganay Duru, Cecilie Blimark, Agneta Swedin, Markus Hansson, Karin Forsberg, Lucia Ahlberg, Conny Carlsson, Anders Waage, Peter Gimsing, Annette Juul Vangsted, Ulf Frølund, Erik Holmberg, Gösta Gahrton, Evren Alici, Mats Hardling, Ulf-Henrik Mellqvist, Hareth Nahi
Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single-agent Len may be effective as prolonged treatment regimen in RRMM once patients demonstrate an initial response to Len+Dex induction. Patients with RRMM who responded to first-line Len+Dex in an observational study (NCT01430546) received up to 24 cycles of either Len (25 mg/day) or Len+Dex (25 mg/day and 40 mg/week) as prolonged treatment in a subsequent phase 2 clinical trial (NCT01450215)...
April 19, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29671538/stable-coronary-artery-disease-treatment
#18
Michael M Braun, William A Stevens, Craig H Barstow
Stable coronary artery disease refers to a reversible supply/demand mismatch related to ischemia, a history of myocardial infarction, or the presence of plaque documented by catheterization or computed tomography angiography. Patients are considered stable if they are asymptomatic or their symptoms are controlled by medications or revascularization. Treatment involves risk factor management, antiplatelet therapy, and antianginal medications. Tobacco cessation, exercise, and weight loss are the most important lifestyle modifications...
March 15, 2018: American Family Physician
https://www.readbyqxmd.com/read/29671196/third-line-therapy-in-recurrent-glioblastoma-is-it-another-chance-for-bevacizumab
#19
Enrico Franceschi, Giuseppe Lamberti, Alexandro Paccapelo, Monica Di Battista, Giovenzio Genestreti, Santino Minichillo, Antonella Mura, Stefania Bartolini, Raffaele Agati, Alba A Brandes
BACKGROUND: Standard glioblastoma therapy is long-lasting. Among second-line therapy, choices could be bevacizumab and nitrosoureas depending on National Agencies approval. There is no consensus on 3rd line therapy or clinical trials specifically designed for this setting. METHODS: We reviewed our institutional database on all consecutive patients who received 3rd line therapy for glioblastoma. RESULTS: Data on 168 out of 1337 (12.6%) glioblastoma patients who underwent 3rd line therapy treatment were collected...
April 18, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29671132/effects-of-county-public-hospital-reform-on-procurement-costs-and-volume-of-antibiotics-a-quasi-natural-experiment-in-hubei-province-china
#20
Yuqing Tang, Chaojie Liu, Junjie Liu, Xinping Zhang, Keyuan Zuo
BACKGROUND: The overuse of antibiotics has become a major public health challenge worldwide, especially in low- and middle-income countries, including China. In 2009, the Chinese government launched a series of measures to de-incentivise over-prescription in public health facilities, including decoupling the link between facility income and the sale of medicines. OBJECTIVES: We evaluated the effects of these measures on procurement costs and the volume of antibiotics in county public hospitals...
April 18, 2018: PharmacoEconomics
keyword
keyword
114245
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"